Granules India Q1 net profit up 41 percent to Rs 51.7 crore
New Delhi: Drug firm Granules India reported a 40.73 percent rise in its consolidated net profit at Rs 51.79 crore for the quarter ended on June 30, 2018.
The company had posted a net profit of Rs 36.80 crore for the corresponding period of the previous fiscal, Granules India said in a filing to BSE.
Consolidated revenue from the operations of the company stood at Rs 453.23 crore for the quarter under consideration as against Rs 384.73 crore for the same period year ago.
Commenting on the development, Granules India Chairman & MD Krishna Prasad Chigurupati said: "The first quarter of the current financial year started on a positive note, We saw our total income increase by 21 percent compared to the same period of previous fiscal."
There was also a sequential growth in margin profiles despite the continuing raw material pricing pressures, he added.
The company said its board has declared a first interim dividend of 25 paise per share of face value of Re 1 each and has also approved the further investment of up to USD 15 million by way of debt/equity in company's wholly-owned arm Granules Pharmaceutical Inc.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd